Table 1.
Ongoing and completed clinical trialsa
| Virus | GBM Type | Study Title | Phase | Biological | n | Duration | NCT Number and Reference | Status |
|---|---|---|---|---|---|---|---|---|
| Adenovirus | Recurrent | DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas | Phase I | DNX-2401 | 37 | February 2009–February 2015 | NCT00805376 20 | Completed |
| Recurrent | Safety Study of Replication-competent Adenovirus (Delta-24-RGD) in Patients With Recurrent Glioblastoma | Phase I-II | DNX-2401 | 20 | June 2010–December 2014 | NCT01582516 | Completed | |
| Recurrent | Virus DNX2401 and Temozolomide in Recurrent Glioblastoma | Phase I | DNX2401 | 31 | September 2013–March 2017 | NCT01956734 | Completed | |
| Recurrent | DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors | Phase I | DNX-2401 | 37 | September 11, 2014–March 15, 2018 | NCT02197169 | Completed | |
| Recurrent | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | Phase II | DNX-2401 | 49 | June 2016–June 2021 | NCT02798406 | Active, not recruiting | |
| Recurrent | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | Phase I | DNX-2440 | 24 | October 16, 2018–October 16, 2022 | NCT03714334 | Recruiting | |
| Recurrent | Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | Phase I | DNX-2401 | 36 | February 12, 2019–May 31, 2022 | NCT03896568 | Recruiting | |
| Herpes | Recurrent | Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma | Phase I | G207 | 21 | February 1998–May 1999 | NCT00036699 32 | Completed |
| Recurrent | Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM | Phase Ib | G207 | 6 | January 2002–August 2003 | NCT00028158 34 | Completed | |
| Recurrent | G207 Followed by Radiation Therapy in Malignant Glioma | Phase I | G207 | 9 | May 2005–December 2008 | NCT00157703 33 | Completed | |
| Recurrent | Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High-Grade Glioma That Can Be Removed By Surgery | Phase I | HSV-1716 | 2 | December 2013–May 2016 | NCT02031965 | Terminated | |
| Recurrent | Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma | Phase I | M032 (NSC 733972) | 15 of 26 | September 2014–September 2023 | NCT02062827 | Recruiting | |
| Recurrent | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | Phase I | G207 | 12 | May 2016–April 2021 | NCT02457845 | Active, not recruiting | |
| Recurrent | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | Phase I | rQNestin34.5v.2 | 108 | July 18, 2017–July 2022 | NCT03152318 | Recruiting | |
| Recurrent | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | Phase I | G207 | 15 | September 12, 2019–September 1, 2024 | NCT03911388 | Recruiting | |
| Recurrent | Trial of C134 in Patients With Recurrent GBM | Phase I | C134 | 24 | September 23, 2019–September 2024 | NCT03657576 | Active, not recruiting | |
| Recurrent | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | Phase II | G207 | 30 | October 1, 2020–October 1, 2024 | NCT04482933 | Not yet recruiting | |
| Measles | Recurrent | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | Phase I | MV-CEA | 23 | October 23, 2006–November 30, 2019 | NCT00390299 | Completed, results not published yet |
| NDV | Recurrent | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | Phase I-II | HUJ | 0 | July 2011–July 2011 | NCT01174537 | Withdrawn |
| Polio | Recurrent | PVSRIPO for Recurrent Glioblastoma (GBM) | Phase I | PVSRIPO | 61 | April 25, 2012–June 2021 | NCT01491893 75 | Active, not recruiting |
| Recurrent | PVSRIPO in Recurrent Malignant Glioma | Phase II | PVSRIPO | 122 | June 1, 2017–December 2023 | NCT02986178 | Active, not recruiting | |
| Recurrent | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | Phase I | PVSRIPO | 12 | December 5, 2017–July 1, 2021 | NCT03043391 | Recruiting | |
| Parvovirus | Recurrent | Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme | Phase I-IIa | H-1PV | 18 | September 2011–May 2015 | NCT01301430 | Completed |
| Reovirus | Recurrent | A Phase I Trial of Intratumoral Administration of Reovirus in Patients With Histologically Confirmed Recurrent Malignant Gliomas | Phase I | Reolysin | 12 | June 2002–July 2005 | N/A89 | Completed |
| Recurrent | Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas | Phase I | Reolysin | 18 | July 2006–June 2010 | NCT00528684 90 | Completed | |
| Recurrent | Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors | Phase I | Reolysin | 6 | June 21, 2015–January 1, 2025 | NCT02444546 | Active, not recruiting | |
| Vaccinia | Recurrent | Safety and Efficacy of the Oncolytic Virus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients | Phase I-II | TG6002 | 78 | October 12, 2017–September 2021 | NCT03294486 | Recruiting |
Abbreviations: HSV, herpes simplex virus; MV-CEA, measles virus carcinoembryonic antigen.
a
Citations are included only for clinical trials with published results.